# NOVT — Novanta Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** NOVT  
**Sources:** 20  
**Published:** 2026-10-24  
**Canonical:** https://app.k3vl4r.com/research/deep-research-novt-novanta-inc-catalysts-narrative-risks-8801

---

# Novanta Inc. (NOVT) — Research Brief as of 2026-10-24

## Recent Catalysts (roughly July–October 2026)

**Q2 2026 earnings (reported August 5–6, 2026) — the dominant recent catalyst.** Novanta reported second-quarter revenue of US$265.81 million, up 10.30% year-over-year, beating consensus of ~US$262.3 million. Adjusted (non-GAAP) diluted EPS came in at US$0.89 against consensus of US$0.83, while GAAP diluted EPS was US$0.30 versus US$0.12 a year earlier, and operating income and adjusted EBITDA both expanded. Management also completed its acquisition of Riverpoint Medical in the quarter and raised full-year guidance (reported reported sales growth of 10%, organic of 9%). [[9]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/novanta-breaks-below-50-day-average-and-baird-sets-usd-194-target-for-novanta-stock/70239337)[[16]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/novanta-stock-sits-19-38-percent-below-its-52-week-high/70210877)[[18]](https://stockanalysis.com/stocks/novt/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-novt-novanta-inc-catalysts-narrative-risks-8801 (free to sign up)._